Contribute Try STAT+ Today

Biotech companies often linger in a corporate version of Schrödinger’s box — of existence and un-existence — for quite some time before officially announcing a “launch.”

Sana Biotechnology, for example, spent a year in limbo before its communications team sent out a press release announcing its launch last October. Thrive Earlier Detection Corp. had its corporate ducks in a row for more than a month before it announced itself. There’s no telling just how many potential biotechs are as-yet-unlaunched, though it’s enough to keep the biotech trade press busy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment